CPHRF (Cipher Pharmaceuticals) ROCE %: 15.13% (As of Mar. 2026)

What is Cipher Pharmaceuticals ROCE %?

Cipher Pharmaceuticals CPHRF 96 ROCE % is 15.13% as of Mar. 2026. GuruFocus rates CPHRF with a GF Score™ of 96/100 and a GF Value™ of $12.19 (Fairly Valued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cipher Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 15.13%.

Cipher Pharmaceuticals (OTCPK:CPHRF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cipher Pharmaceuticals ROCE % Related Terms

Cipher Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Cipher Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipher Pharmaceuticals ROCE % Chart

Cipher Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

35.43

21.30

14.19

7.03

12.31

Cipher Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															6.54	14.25	15.20	13.70	15.13

96GF Score

Cipher Pharmaceuticals Inc CPHRF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cipher Pharmaceuticals ROCE % Calculation

Cipher Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	16.865	/	( ( (162.512 - 19.874)	+	(156.502 - 25.042) )	/ 2 )
	=	16.865	/	( (142.638	+	131.46)	/ 2 )
	=	16.865	/	137.049
	=	12.31 %

Cipher Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	20	/	( ( (156.502 - 25.042)	+	(153.279 - 20.368) )	/ 2 )
	=	20	/	( ( 131.46	+	132.911 )	/ 2 )
	=	20	/	132.1855
	=	15.13 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 15.13% mean?

Cipher Pharmaceuticals (CPHRF) has a ROCE % of 15.13% as of Mar. 2026.

Is Cipher Pharmaceuticals' ROCE % too high?

Cipher Pharmaceuticals' current ROCE % is 15.13%. The Drug Manufacturers industry median ROCE % is 7.00. Cipher Pharmaceuticals' value of 15.13% is 116.3% above this industry median. Overall, Cipher Pharmaceuticals has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Cipher Pharmaceuticals' ROCE % compare to ZTS?

Cipher Pharmaceuticals' ROCE % of 15.13% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Cipher Pharmaceuticals' value of 15.13% is 116.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipher Pharmaceuticals's current ROCE % of 15.13% is 116.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipher Pharmaceuticals's current ROCE % is 15.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cipher Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Cipher Pharmaceuticals (CPHRF) is currently considered Fairly Valued. The stock's GF Value™ is $12.19, compared to a current price of $11.43 — trading 6.2% below its estimated fair value. The current ROCE % is 15.13% and 116.3% above the Drug Manufacturers industry median of 7.00. Cipher Pharmaceuticals' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Cipher Pharmaceuticals (CPHRF), the current ROCE % is 15.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipher Pharmaceuticals (CPHRF) Overvalued in 2026?

Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued. The current stock price of $11.43 is trading 6.2% below its estimated GF Value™ of $12.19. GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.

Key valuation signals for CPHRF:

ROCE %: 15.13%
GF Value™: $12.19 vs. price of $11.43 (6.2% below fair value)
GF Score™: 96/100 with 5 warning signs
Industry Position: 116.3% above the Drug Manufacturers median

No single metric tells the full story. See the CPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipher Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XCNQ:CL TSX:TSND TSX:ACB NEOE:VRNO TSX:OGI TSX:XLY TSX:WEED TSX:CRDL TSX:CWEB TSX:LOVE XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges PHE:Germany CPH:Canada

Address 5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9

Website https://www.cipherpharma.com

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.

96GF Score

Get the complete analysis for CPHRF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.43

Price

$12.19

GF Value

View CPHRF Analysis

See ROCE % data for all stocks →